Objective:To investigate the effects of propofol and ketamine on seizure duration,hemodynamics,and recovery of electroconvulsive therapy(ECT).Methods:This prospective randomized trial included patients who had undergo...Objective:To investigate the effects of propofol and ketamine on seizure duration,hemodynamics,and recovery of electroconvulsive therapy(ECT).Methods:This prospective randomized trial included patients who had undergone ECT under anesthesia.Patients received injection of propofol 1.5 mg/kg i.v.(the propofol group)or ketamine 0.8-1.2 mg/kg i.v.(the ketamine group)during ECT.Seizure duration,hemodynamics,and recovery were recorded and compared between the two groups.Results:This trial included 44 patinets with 22 patients receiving propofol and 22 patients receiving ketamine.The total dose of propofol and ketamine was(105.68±25.27)mg and(81.36±24.55)mg,respectively.The motor seizure and electroencephalogram seizure duration were prolonged in the ketamine group(P<0.001).The hemodynamics at the admission of the two groups were comparable(P>0.05);however,the mean systolic blood pressure during the procedure was significantly higher in the ketamine group(P=0.04).Besides,spontaneous eye-opening in the ketamine group took longer than that of the propofol group(P=0.001).Conclusion:Both propofol and ketamine are safe as anesthetic agents for modified ECT,and ketamine provides a longer seizure duration without hemodynamic instability or any significant complication.展开更多
It is a retrospective qualitative study of all patients that had received ECT treatment in Khartoum National Psychiatric Hospitals in the period between January 2010 and December 2010 with special reference to indicat...It is a retrospective qualitative study of all patients that had received ECT treatment in Khartoum National Psychiatric Hospitals in the period between January 2010 and December 2010 with special reference to indications, side effects, and outcome using the same outcome criteria used by the royal college of Psychiatrists (UK) for modified audit format. 85% from 269 of overall Sudanese patients who had received ECT showed remarkable clinical response, with no major adverse side effects. Interestingly, the response rate was over 90% for patients with mania spectrum diagnosis. 85% of our patients were under the age of 40. Two thirds of the patients, who received ECT, were male. The main indication for ECT (45%) was mania, while depression and mixed affective states constituted less than 25% of the sample. Conclusion: In comparison to the West, ECT plays a major role in the treatment of mania and manic spectrum disorders in Africa.展开更多
ECT is most often used as a treatment for severe major depression which has not responded to other treatment, and it is also used in the treatment of mania (often in bipolar disorder), and catatonia. Its use for obesi...ECT is most often used as a treatment for severe major depression which has not responded to other treatment, and it is also used in the treatment of mania (often in bipolar disorder), and catatonia. Its use for obesity treatment was never suggested before. However, incidental information from several studies revealed that “Five of 10 patients were obese pre-ECT, all of whom had a significant weight loss after ECT.” and “Once-daily ECS over 10 days (which significantly reduced weight gain in rats)”. A new hypothesis is made for the use of ECT for obesity treatment.展开更多
<strong>Objective:</strong> This study was conducted to discern the efficacy of maintenance electroconvulsive therapy (M-ECT) in a population of depressed elderly individuals with treatment-resistant depre...<strong>Objective:</strong> This study was conducted to discern the efficacy of maintenance electroconvulsive therapy (M-ECT) in a population of depressed elderly individuals with treatment-resistant depression. <strong>Methodology:</strong> Twenty-nine (N = 29) individuals over the age of 65 years of age and older were assigned to a control or treatment group on the basis of their decision to receive M-ECT (treatment group) or to refrain from receiving the treatment (control group). A battery of psychometric tests designed to measure severity of depression, quality of life, and cognition were administered at baseline as well as at 6-month and 1-year intervals. <strong>Results:</strong> Statistical analysis of the data indicated no significant differences in the efficacy of M-ECT between the control and treatment groups in any of the tests administered during the participation of the study. <strong>Conclusion:</strong> The results of the study suggest that there is no added benefit for patients administered M-ECT. However, study sample size and availability of alternative treatment regimens for the control group limit generalizability of these findings and warrant further investigation.展开更多
文摘Objective:To investigate the effects of propofol and ketamine on seizure duration,hemodynamics,and recovery of electroconvulsive therapy(ECT).Methods:This prospective randomized trial included patients who had undergone ECT under anesthesia.Patients received injection of propofol 1.5 mg/kg i.v.(the propofol group)or ketamine 0.8-1.2 mg/kg i.v.(the ketamine group)during ECT.Seizure duration,hemodynamics,and recovery were recorded and compared between the two groups.Results:This trial included 44 patinets with 22 patients receiving propofol and 22 patients receiving ketamine.The total dose of propofol and ketamine was(105.68±25.27)mg and(81.36±24.55)mg,respectively.The motor seizure and electroencephalogram seizure duration were prolonged in the ketamine group(P<0.001).The hemodynamics at the admission of the two groups were comparable(P>0.05);however,the mean systolic blood pressure during the procedure was significantly higher in the ketamine group(P=0.04).Besides,spontaneous eye-opening in the ketamine group took longer than that of the propofol group(P=0.001).Conclusion:Both propofol and ketamine are safe as anesthetic agents for modified ECT,and ketamine provides a longer seizure duration without hemodynamic instability or any significant complication.
文摘It is a retrospective qualitative study of all patients that had received ECT treatment in Khartoum National Psychiatric Hospitals in the period between January 2010 and December 2010 with special reference to indications, side effects, and outcome using the same outcome criteria used by the royal college of Psychiatrists (UK) for modified audit format. 85% from 269 of overall Sudanese patients who had received ECT showed remarkable clinical response, with no major adverse side effects. Interestingly, the response rate was over 90% for patients with mania spectrum diagnosis. 85% of our patients were under the age of 40. Two thirds of the patients, who received ECT, were male. The main indication for ECT (45%) was mania, while depression and mixed affective states constituted less than 25% of the sample. Conclusion: In comparison to the West, ECT plays a major role in the treatment of mania and manic spectrum disorders in Africa.
文摘ECT is most often used as a treatment for severe major depression which has not responded to other treatment, and it is also used in the treatment of mania (often in bipolar disorder), and catatonia. Its use for obesity treatment was never suggested before. However, incidental information from several studies revealed that “Five of 10 patients were obese pre-ECT, all of whom had a significant weight loss after ECT.” and “Once-daily ECS over 10 days (which significantly reduced weight gain in rats)”. A new hypothesis is made for the use of ECT for obesity treatment.
文摘<strong>Objective:</strong> This study was conducted to discern the efficacy of maintenance electroconvulsive therapy (M-ECT) in a population of depressed elderly individuals with treatment-resistant depression. <strong>Methodology:</strong> Twenty-nine (N = 29) individuals over the age of 65 years of age and older were assigned to a control or treatment group on the basis of their decision to receive M-ECT (treatment group) or to refrain from receiving the treatment (control group). A battery of psychometric tests designed to measure severity of depression, quality of life, and cognition were administered at baseline as well as at 6-month and 1-year intervals. <strong>Results:</strong> Statistical analysis of the data indicated no significant differences in the efficacy of M-ECT between the control and treatment groups in any of the tests administered during the participation of the study. <strong>Conclusion:</strong> The results of the study suggest that there is no added benefit for patients administered M-ECT. However, study sample size and availability of alternative treatment regimens for the control group limit generalizability of these findings and warrant further investigation.
